Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients.

Journal of comparative effectiveness research - 1 Jan 2022

Moya-Alarcón Carlota, Piera Guiomar, Callejo Ángel, Gascó Amaya

Abstract excerpt

Aim: To describe the overall cancer-related healthcare utilization patterns, treatment patterns and outcomes in women diagnosed with platinum-sensitive recurrent high-grade serous ovarian cancer. Patients & methods: Subanalysis of the Spanish sample of a retrospective, noninterventional, multinational, observational study. Results:BRCA-mutated patients had better outcomes in terms of progression-free survival and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Treatment Outcome

Source

Identifiers

PMID: 34697945
DOI: 10.2217/cer-2021-0135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients.PMID 34697945Read ↗

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.Semantic proximity Read ↗

Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.Semantic proximity Read ↗

Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.Semantic proximity Read ↗

The Role of Secondary Cytoreductive Surgery in Primary Platinum-sensitive Recurrent HGSOC Patients With Different BRCA1/2 Mutation Status: a Retrospective StudySemantic proximity Read ↗

Platinum-Based Chemotherapy Versus Secondary Cytoreductive Surgery Before Olaparib Maintenance Therapy for 259 Patients with BRCA Mutated Platinum-Sensitive Recurrent Ovarian Cancer: A Multicenter Retrospective Study: Comparative Effectiveness and Survival Outcomes Analysis.Semantic proximity Read ↗

Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.Semantic proximity Read ↗

BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction.Semantic proximity Read ↗

Study finds different treatment responses between BRCA2- and BRCA1-mutated ovarian cancers.Semantic proximity Read ↗

Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.Semantic proximity Read ↗

Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancerSemantic proximity Read ↗

Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based ChemotherapySemantic proximity Read ↗

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.